Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Depreciation (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Accumulated Depreciation for 3 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation rose 24.81% to $1.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.3 million, a 24.81% increase, with the full-year FY2024 number at $1.3 million, up 24.81% from a year prior.
  • Accumulated Depreciation was $1.3 million for Q4 2024 at Orchestra BioMed Holdings, up from $1.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.3 million in Q4 2024 to a low of $778000.0 in Q4 2022.
  • A 3-year average of $1.1 million and a median of $1.1 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 34.19% in 2023, then increased 24.81% in 2024.
  • Orchestra BioMed Holdings' Accumulated Depreciation stood at $778000.0 in 2022, then surged by 34.19% to $1.0 million in 2023, then rose by 24.81% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for OBIO's Accumulated Depreciation are $1.3 million (Q4 2024), $1.2 million (Q3 2024), and $1.0 million (Q4 2023).